Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2024	Polar Asset Management Partners Inc.	1,577,387	$0.58M	0.0%	-20.6%	0.924%
11/15/2024	HGC Investment Management Inc.	223,077	$82K	0.0%	N/A	0.131%
5/9/2024	Portland Global Advisors LLC	5,782,209	$21.68M	3.0%	N/A	36.550%

Data available starting January 2016

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Today's Range

Now: $1.07

$1.01

$1.27

50 Day Range

MA: $1.51

$0.86

$3.05

52 Week Range

Now: $1.07

$0.26

$21.09

Volume

3,608,382 shs

Average Volume

2,620,707 shs

Market Capitalization

$187.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Tevogen Bio?: Tevogen Bio's top insider investors include:
Kirti Desai (CFO)
Neal Flomenberg (Insider)
Learn More about top insider investors at Tevogen Bio.
Who are the major institutional investors of Tevogen Bio?: Tevogen Bio's top institutional investors include:
Polar Asset Management Partners Inc. — 0.92%
HGC Investment Management Inc. — 0.13%
Learn More about top institutional investors of Tevogen Bio stock.
Which institutional investors are selling Tevogen Bio stock?: In the previous quarter, TVGN stock was sold by these institutional investors:
Polar Asset Management Partners Inc.
Which institutional investors are buying Tevogen Bio stock?: During the last quarter, TVGN stock was acquired by institutional investors including:
HGC Investment Management Inc.